STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNDM
  4. [Form 4] Tandem Diabetes Care, Inc. Insider Trading Activity

Tandem Diabetes Care Director Adds 1,749 Shares After RSU Conversion

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Form 4 filing: On 18-Jun-2025 Tandem Diabetes Care (TNDM) reported that director Joao Paulo Falcao Malagueira acquired 1,749 common shares on 16-Jun-2025 through the automatic settlement of previously granted restricted stock units (RSUs). The RSUs were awarded on 15-Jun-2022 under the company’s 2013 Stock Incentive Plan and vest in three equal annual instalments. No cash consideration was paid (exercise price $0).

Following the conversion, the director’s direct ownership increases to 13,699 TNDM shares. The transaction is coded “M,” indicating a routine equity award vesting rather than an open-market trade, and leaves no remaining derivative securities from this grant. The filing does not signal any strategic or operational changes at the company.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine RSU vesting; director adds 1,749 shares; negligible market impact.

The Form 4 shows a standard "M" transaction—conversion of RSUs into common stock at no cost. While insider share accumulation can be viewed positively, the size (1,749 shares) is immaterial relative to Tandem Diabetes Care’s 64 million-plus shares outstanding. No open-market buying or selling occurred, and beneficial ownership now totals 13,699 shares. The transaction does not alter insider ownership percentages or convey new information about business performance. Consequently, the filing is best interpreted as housekeeping under the equity compensation plan, with limited relevance for valuation or near-term trading.

Insider Malagueira Joao Paulo Falcao
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Unit 1,749 $0.00 --
Exercise Common Stock 1,749 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 13,699 shares (Direct)
Footnotes (1)
  1. Awarded on June 15, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. The total number of shares subject to the RSU will vest over a period of three years in equal annual installments on the anniversary of the grant, subject to the terms of the 2013 Plan.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Malagueira Joao Paulo Falcao
(Last) (First) (Middle)
12400 HIGH BLUFF DRIVE
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/16/2025 M 1,749 A $0 13,699 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit(1) (2) 06/16/2025 M 1,749 (3) (3) Common Stock 1,749 $0 0 D
Explanation of Responses:
1. Awarded on June 15, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).
2. Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
3. The total number of shares subject to the RSU will vest over a period of three years in equal annual installments on the anniversary of the grant, subject to the terms of the 2013 Plan.
Remarks:
/s/ Rachel Malina, Attorney-in-Fact for Joao Paulo Falcao Malagueira 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity was reported for TNDM in the latest Form 4?

Director Joao Paulo Falcao Malagueira acquired 1,749 common shares via vested RSUs on 16-Jun-2025.

How many Tandem Diabetes Care shares does the director now own?

Post-transaction, the director holds 13,699 TNDM shares directly.

Was any cash paid for the acquired TNDM shares?

No. The shares were issued at $0 exercise price as part of an RSU settlement.

When were the RSUs that vested originally granted?

The RSUs were granted on 15-Jun-2022 under the 2013 Stock Incentive Plan.

Does the filing indicate any open-market buying or selling by the director?

No. The code "M" denotes an RSU conversion, not an open-market trade.